c19early.org COVID-19 treatment researchCOVID-19 treatments

Supplementary Data — Interferon-α for hantavirus: real-time meta-analysis of 1 study

@CovidAnalysis, November 2026, Version 1V1

Interferon-α hantavirus outcomes

c19early.org
November 2026
StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Gui (RCT)0%1.00 · 0.28–3.56death4/254/25HFRS, Hantann Gui (RCT)67%0.33 · 0.04–2.99progression1/253/25HFRS, Hantann Gui (RCT)43%0.57 · 0.19–1.71progression4/257/25HFRS, Hantann Gui (RCT)−32%1.32 · 1.24–1.42no recov.25 (n)25 (n)HFRS, Hantann
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Interferon-α
reduces riskInterferon-α
increases risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.